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Abstract
Doxorubicin (Dox) is an anthracycline used to effectively treat several forms of cancer. Unfortunately, the use of Dox is
limited due to its association with cardiovascular complications which are manifested as acute and chronic cardiotoxicity.
The pathophysiological mechanism of Dox induced cardiotoxicity appears to involve increased expression of the tumor
suppressor protein p53 in cardiomyocytes, followed by cellular apoptosis. It is not known whether downregulation of p53
expression in cardiomyocytes would result in decreased rates of myocardial fibrosis which occurs in response to
cardiomyocyte loss. Further, it is not known whether Dox can induce perivascular necrosis and associated fibrosis in the
heart. In this study we measured the effects of acute Dox treatment on myocardial and perivascular apoptosis and fibrosis in
a conditional knockout (CKO) mouse model system which harbours inactive p53 alleles specifically in cardiomyocytes. CKO
mice treated with a single dose of Dox (20 mg/kg), did not display lower levels of myocardial apoptosis or reactive oxygen
and nitrogen species (ROS/RNS) compared to control mice with intact p53 alleles. Interestingly, CKO mice also displayed
higher levels of interstitial and perivascular fibrosis compared to controls 3 or 7 days after Dox treatment. Additionally, the
decrease in levels of the microtubule protein a-tubulin, which occurs in response to Dox treatment, was not prevented in
CKO mice. Overall, these results indicate that selective loss of p53 in cardiomyocytes is not sufficient to prevent Dox induced
myocardial ROS/RNS generation, apoptosis, interstitial fibrosis and perivascular fibrosis. Further, these results support a role
for p53 independent apoptotic pathways leading to Dox induced myocardial damage and highlight the importance of
vascular lesions in Dox induced cardiotoxicity.
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Introduction
Doxorubicin (Dox) is a member of Anthracycline (ANT) family
of anticancer drugs. ANTs are frequently administered due to a
strong correlation between dose and efficacy [1]. The use of ANTs
for cancer treatment can lead to a series of pathophysiological
complications such as tumor cell resistance and cellular toxicity.
Cardiotoxicity is particularly prevalent in many patients which
leads to cardiomyocyte apoptosis, myocardial fibrosis, cardiomy-
opathy, arrhythmias and congestive heart failure (CHF) [2]. While
several distinct mechanisms have been reported as underlying
causes of Dox-induced cytotoxicity, it is well established that the
tumor suppressor protein p53 plays a key role in Dox-induced
apoptosis in cardiomyocytes as well as cancer cells [3].
Dox induces tumor cell apoptosis mainly due to its function as a
topoisomerase II (topo-II) inhibitor [4]. The formation of a ternary
complex consisting of Dox-DNA-topo II blocks the ligation step of
DNA synthesis cycle and causes single and double strand DNA
breaks which ultimately leads to cellular apoptosis [5]. In contrast
to cancer cells, accumulation of reactive oxygen and nitrogen
species (ROS/RNS) and changes in the mitochondrial membrane
permeability are the predominant cause of Dox-induced apoptosis
in cardiomyocytes and endothelial cells [6–8]. Compared to
cancer cells, cardiomyocytes are more suceptible to Dox induced
free radical damage due to lower levels of catalase [9], an enzyme
which serves as a defense mechanism in converting hydrogen
peroxide to water and oxygen [10]. It has been proposed that Dox
initially increases mitochondrial superoxide and other ROS
products via redox cycling followed by generation of NO and
other RNS (e.g. peroxynitrite) and subsequently causes an
increased expression of NF-kB and inducible nitric oxide synthase
(iNOS) [7]. Concerted actions of ROS/RNS have been further
implicated in the amplification of oxidative/nitrosactive stress
pathways, DNA damage, redox regulation of p53 transcription
and posttranslational modifications as well as apoptosis [8]. Some
studies have shown that Dox can trigger release of cytochrome c
from mitochondria or inhibit electron transport chain and cause
apoptosis regardless of DNA damage or p53 levels [11–14].
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effectively block Dox induced cardiotoxicity. These include:
administration of antioxidants [15], scavengers of peroxynitrite
[7], iron chelating agents [16] and glutamate [17], inhibition of
endocannabinoids [6,18], treatment with factors such as erythro-
poietin [19] or granulocyte stimulating factor [20] and abrogation
of p53 activity via global knockdown [21] or chemical inhibition
[22] approaches. More recently, Zhu et al. have shown that
blocking p53 in a cardiomyocyte restricted manner was sufficient
to prevent systolic dysfunction and reduction in cardiac mass
induced by acute Dox treatment for seven days [23]. However,
these studies did not determine whether short term functional
improvement seen in response to p53 abrogation is due to a
decreased rate of myocardial fibrosis, a well established risk factor
for arrhythmia, cardiomyopathy and CHF [24,25]. Further, it has
not been determined whether Dox administration would lead to
perivascular necrosis and associated fibrosis in myocardial tissue
from animals with normal or compromised p53 function.
Monitoring these aspects is particularly important because Dox
treatment is well known to cause a late-onset refractory
cardiomyopathy and heart failure [26].
In this study, we have developed a conditional knockout (CKO)
mouse model system to facilitate cardiomyocyte specific removal of
sequences encoding the p53 gene. To determine whether p53
expression in cardiomyocytes plays any direct role in the onset of
cardiac fibrosis in heart tissue, we studied wild type and p53-CKO
mice subjected to Dox treatment for various time periods.
Reparative myocardial fibrosis reminiscent of myocyte death was
present in both wild type and p53-CKO hearts subjected to Dox
treatment. We also observed increased incidence of perivascular
fibrosis in myocardial sections from Dox treated wild type and
p53-CKO mice compared to saline treated mice. Further, we
found a significant decrease in the expression levels of a-tubulin, a
microtubular protein essential for normal cardiac function, in both
wild type and p53-CKO mice 3 days post Dox treatment.
Collectively our results suggest that selective loss of p53 in
cardiomyocytes is not sufficient to block myocardial fibrosis and
loss of microtubule proteins in acute phase of Dox treatment.
These results underscore the importance of p53 independent
pathways as well as vascular lesions in Dox induced cardiotoxicity.
Materials and Methods
Ethics Statement
All animal procedures were performed according to the
Canadian Council on Animal Care guidelines and were approved
by the Dalhousie University Committee on Laboratory Animal
Care (Protocol#10-008; 09-038).
Generation and Genotyping of Mice
Cardiomyocyte specific deletion of p53 was accomplished by
Cre-lox based technology. Generation of mice with Cre recombi-
nase inserted into the coding sequence of Mesp1 was previously
described[27].Mesp1isexpressedinearlymesodermattheonsetof
gastrulation, including heart precursor cells. Only Mesp1-Cre
heterozygous mice (MC
+/2) were used in this study as the
homozygous Cre mice (MC
+/+) were embryonic lethal [27].
Similarly, generation of mice with loxP sites inserted into introns
1 and 10 of the p53 gene (p53 floxed allele or p53
F2-10, Figure 1A)
was previously described [28]. Both strains of mice were maintained
in C57BL6/J (BL6) background. For control comparisons, BL6 and
CD1 mice were purchased from Jackson (Maine, MA) and Chrales
River Laboratories (Wilmington) respectively. Efficient Cre medi-
ated removal of the p53 coding sequence between loxP sites was
accomplished by crossing floxed p53
F2-10 mice (heterozygous
designated p53
F/+ and homozygous designated p53
F/F) with mice
expressing Mesp1-Cre (designated MC
+). To confirm the genotype
of offsprings, genomic DNA was extracted from ear punch biopsies
and a polymerase chain reaction (PCR) amplification assay was
performed using RedExtract amplification kit (Sigma) and appro-
priate primer sets for MC and p53 transgenes (Fig. 1A and B, see
Table 1 for sequences). To confirm the deletion of exons 2–10
corresponding to p53 allele (p53
DF2-10, Fig. 1A), genomic DNA was
extracted from heart tissue and PCR was performed using primer
pairs 1FAand 10RA (Fig. 1C and Table 1).PCRconditions forMC
transgene amplification were 95uC3 0s e c ,6 0 uC 30 sec, 72uC 30 sec
for 30 cycles. Similarly, PCR conditions for p53 alleles were 94uC
30 sec, 68uC 1 min, 72uC 2 min for 30 cycles.
Doxorubicin Injections and Sample preparation
MC
+p53
F/F and MC
+p53
F/+ male mice aged 11–15 weeks were
injected intraperitoneally with a single dose of either Doxorubicin
Hydrochloride (20 mg/kg, Mayne Pharma, Montreal, QC) or
saline. Age and sex matched control BL6 mice which were
negative for either the MC transgene or p53 floxed allele were also
processed using the same injection protocol. Mice were sacrificed
by cervical dislocation after 3 or 7 days post Dox injection and
heart tissues were subsequently collected, weighed and divided into
three parts. The top third of each heart was stored at 280uC and
subsequently used for p53 western blot analysis. The bottom two
thirds were placed in 30% sucrose solution overnight at 4u for
cryoprotection, subsequently embedded in tissue freezing medium
(Tissue-tek, O.C.T., Sakura Finetek, Japan), frozen at 280uC and
processed for histological analysis. Thin tissue sections (10 mm)
were generated using a Leica CM 3050 S Cyrostat. Heart weight
to body weight ratios were calculated to examine whether the
genomic modification had any significant impact on the
physiology of the mice. Each treatment group consisted of three
to five mice. For a comparison of myocardial fibrotic lesions
induced by Dox with those induced by excessive catecholamines,
cardiac hypertrophy was induced in 11–15 week old male CD1
mice by implanting mini-osmotic pumps filled with sterile saline
containing isoproterenol as described in our earlier study [29].
Immunofluorescence staining of Myocardial Sections
To study the effect of Dox treatment on p53 expression, thin
cryosections were generated as described earlier [30]. Sections
were fixed in methanol for 15 minutes at 4uC and blocked with
10% goat serum and 1% bovine serum albumin (BSA) in PBS for
60 minutes. Parallel sections were incubated with rabbit polyclon-
al antibodies directed against p53 (SC-6243; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or Von Willebrand Factor
(VWF, SC-14014; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Sections were subsequently incubated with goat anti-rabbit
secondary antibodies conjugated to Alexa Fluor 555 (Invitrogen,
Carlsbad, CA, USA) for those probed for p53 expression or Alexa
Fluor 488 (Invitrogen, Carlsbad, CA, USA) for those probed for
VWF protein. Nuclei were stained with 10 mg/ml of Hoechst
33342 for 5 minutes. Samples were mounted in 1% propyl gallate
solution and examined using a Leica DM2500 fluorescence
microscope (Leica Microsystem). Images were captured using a
Leica DFC 500 digital acquisition system.
Polyacrylamide Gel Electrophoresis (PAGE) and Western
Blot Analysis
Mouse hearts were homogenized in tumor lysis buffer [1%
NP40, 5 mM EDTA, 50 mM Tris-HCl pH 8.0, phenylmethylsul-
p53 Independent Doxorubicin Cardiotoxicity
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described earlier [31]. Lysates were sonicated and centrifuged at
13,500 rpm for 15 minutes at 4uC. Supernatants were collected
and protein concentrations were estimated by the Bradford assay
(Pierce). 40 mg of protein was denatured in Laemmli buffer and
separated in denaturing conditions on a 12.5% SDS-PAGE gel
and transferred onto a nitrocellulose membrane. Blots were
routinely stained with 0.1% Naphthol blue black (Sigma-Aldrich)
to determine the amount of protein loading. Membranes were
blocked (5% milk, 3% BSA, 0.1% Tween in PBS), and incubated
with antibodies specific for p53 (SC-6243), CBF-A (SC-13045) and
a-tubulin (SC-8035) followed by incubation with anti-rabbit or
anti-mouse antibodies conjugated to horse radish peroxidase.
Signals were visualized using the ECL method (GE Healthcare). In
some cases, imaging films were scanned and analyzed by NIH
ImageJ software. The linear range of a density curve was selected
for calculations. The levels of a-tubulin were normalized to those
of CBF-A for each sample in order to correct for any variations in
protein loads. Adjusted values were further normalized to the
protein levels in the control saline treated samples. The
densitometry data are presented as relative changes from control
levels 6 SEM.
Terminal deoxynucleotidyl transferase-mediated dUTP
Nick End Labelling (TUNEL) and Active Caspase 3 (Casp3)
Staining
The TUNEL assay was performed for detection of apoptosis in
myocardial sections using TMR Red In Situ cell death detection kit
according to manufacturer’s instructions (Roche Applied Science,
Mannheim, Germany). Slides were fixed in 4% paraformaldehyde
for 1 hour at room temperature, processed for TUNEL assay, then
washed with PBS and labelled with Hoechst 33258 (10 mg/ml) at
Figure 1. Generation and characterization of p53 conditional knockout mice. (A) Schematic representation of transgenic alleles
corresponding to MesP1-Cre (MC), floxed p53 (p53
F2-10) and conditional p53 deletion (p53
DF2-10) mice. Positions of exons and loxP sites are indicated
by numbered black boxes and arrowheads respectively. Positions of primer pairs used for genotyping are indicated by arrows. (B) MC positive (+) and
negative (2) mice were identified by PCR amplification of ear punch genomic DNA using NeoAL and GR1 primers. Mice homozygous (F/F) or
heterozygous (F/+) for floxed p53 alleles were identified using 10FM and 10RM primers. Wt: wild type; H2O: no template control for PCR. (C) Excision
of exons 2–10 of p53 gene in double transgenic hearts (MC
+ and p53
F/F or
F/+) was confirmed by PCR amplification of cardiac genomic DNA using 1FA
and 10RA primers. Note the absence of PCR amplification product with 1FA/10RA primers in MC
2 p53
F/F mice. Excision of p53 exons does not occur
in MesP1 negative non-cardiacmyocytes. As a result, primers specific for intron 10 (10FA/10RA) and intron 1 (1FA/1RA) can also amplify PCR products
from cardiac genomic DNA.
doi:10.1371/journal.pone.0022801.g001
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with PBS and mounted with propyl gallate solution. Apoptotic
cells were detected using a Lecia DM2500 microscope with
appropriate filters. Negative control consisted of the labelling
solution without the enzyme solution.
For active Caspase 3 (Casp3) staining, cryosections were
hydrated in PBS and fixed in formalin for 15 min. Sections were
subsequently quenched in 0.3% hydrogen peroxide for 30 min,
blocked for 5 hours and incubated with anti-active Casp3
antibody (G7481, Promega, Madison) overnight at 4uC followed
by secondary antibody detection reagents from Vectastain ABC
system (Vector Labs) according to the instructions provided by the
supplier. Signal was visualized using the diaminobenzidine (DAB)
solution (1 DAB tablet (Sigma), 0.375 g Nickel Ammonium Sulfate
and 1.5 ml of 3% hydrogen peroxide dissolved in 62.5 ml of TBS,
pH 8). Slides were immersed in DAB solution for 10 min,
dehydrated in graded ethanol (70%, 95% and 100%), xylene
and mounted using cytoseal-60 (Richard-Allan Scientific). All
Casp3 staining steps were performed at room temperature unless
otherwise specified.
Assessment of Superoxide and 3-Nitrotyrosine (3-NT)
Levels in Myocardial Sections
Unfixed cryosections were hydrated in PBS, incubated with
5 mM dihydroethidium (DHE, Invitrogen) at 37uC for 30 min,
rinsed with PBS and mounted using propyl gallate solution. DHE
fluorescence was imaged using a Zeiss LSM 510 Meta confocal
microscope as recommended in previous studies [32]. For
detection of 3-NT, cryosections were fixed and immunostained
with 3-NT antibodies (#sc-55256, Santa Cruz, CA) using
Vectastain ABC system similar to that described for Casp3
staining procedure.
Quantification of Fibrosis
To determine the extent of fibrosis due to Dox treatment,
cryosections were processed for Picro Sirius Red and Fast Green
staining as described earlier [29]. Slides were fixed in Bouins
solution at 55uC for 1 hour, washed with water, stained with 0.1%
Fast Green (Sigma) at room temperature for 10 minutes, washed
with 0.1% acetic acid for two minutes, and stained with 0.1% Pico
Sirius Red for 30 minutes (Sigma-Direct red 80 in saturated
aqueous picric acid). The slides were dehydrated in an ascending
grade of 70, 95, and 100% ethanol for approximately 2 minutes
per wash, cleared in xylene solution for 2 minutes and mounted in
cytoseal-60. Quantification of cardiac fibrosis was performed via
Colour-Subtractive Computer-Assisted Image Analysis (CS-CAIA)
as described previously [29]. Areas occupied by green pixels
(representing healthy cardiac tissue) and areas occupied with red
pixels (representing fibrotic tissue) from photomicrographs were
assessed by an image processing software developed by Reindeer
Graphics (Asheville, NC, USA). Percent fibrosis was calculated
based on the area occupied by red pixels divided by the sum of
area occupied by red and green pixels multiplied by one hundred.
Each treatment group consisted of three to five mice, of which ten
sections per heart were sampled for fibrosis quantification.
Statistical Analysis
Data are presented as the mean 6 SEM. Multiple group
comparisons for heart weight body weight ratios, active caspase
levels, fibrosis assessment, a-tubulin and CBF-A levels were
analyzed by ANOVA with Tukey’s multiple comparison tests
using Graphpad Prism 4 (GraphPad software, San Diego, CA).
Significance was assumed at P,0.05.
Results
Conditional excision of p53 exons 2–10 in adult mouse
cardiomyocytes
The aim of this study was to determine the role of p53
expression in cardiomyocytes and vascular cells in the context of
Dox-induced cardiotoxicity. To this end, we crossed mice
expressing Cre recombinase exclusively in cardiomyocytes (MC
+)
with mice harboring floxed p53
F2-10 alleles and generated
cardiomyocyte specific p53 CKO mice (Fig. 1A). The MC
+
offsprings could be readily identified by amplification of a 1080 bp
fragment from the ear punch genomic DNA using NeoAL and
GR1 primers (Fig. 1B and Table 1). PCR amplification of ear
punch genomic DNA using intron 10 specific primers of p53
(10FM/10RM) yielded 585 bp and or 432 bp products. Ampli-
fication of both fragments confirmed the identity of mice as
heterozygous for floxed p53
F2-10 allele (p53
F/+). In contrast, mice
homozygous for floxed (p53
F/F) or wild type p53 alleles were
identified by exclusive amplification of 585 bp or 432 bp bands
respectively (Fig. 1B). Similarly, another intron 10 specific primer
pair (10FA/10RA) and intron 1 specific primer pair (1FA/1RA)
were also used to identify p53
F/+, p53
F/F and wild type genotypes
(Table 1). Using this Cre-lox approach, sequences corresponding
to exons 2–10 of p53 allele are expected to remain intact in non-
cardiac tissue. Accordingly, all p53 primer pairs could efficiently
Table 1. Primers used for genotyping analysis.
Gene Primer pairs (59 to 39) Amplicon size (bp)
MesP1-Cre Neo AL: GAAAGAACCAGCTGGGGCTCGAG 1080
GR1: ATATGCCAAGTCATTGAGGTGAGCTTTC
p53 Floxed allele (intron 10) 10FM: AAGCTGAAGACAGAAAAGGGGAGGG 585 (floxed allele)
10RM: AAGCTAAGGGGTATGAGGGACAAGG 432 (wild type)
p53 Floxed allele (intron 10) 10FA: GTAAGTGGCCTGGGGCAGCG 722 (floxed allele)
10RA: GGGGAGGGATGAAGTGATGGGAGC 569 (wild type)
p53 Floxed allele (intron 1) 1FA: GCGACTGACTGTGCCCTCCGT 450 (floxed allele)
1RA: GGAACCATCGCTTTCGCACCTTGG 368 (wild type)
p53 Deletion allele (p53
DF2-10) 1FA: GCGACTGACTGTGCCCTCCGT 603
10RA: GGGGAGGGATGAAGTGATGGGAGC
doi:10.1371/journal.pone.0022801.t001
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type or transgenic mice.
In contrast to ear punch biopsies, expression of Cre recombi-
nase in MC
+ p53
F/+ or MC
+p53
F/F double transgenic hearts is
expected to facilitate excision of exons 2–10 of p53 allele
exclusively in cardiomyocytes. This is due to the fact that Mesp1
transcription factor is expressed in early cardiomyocyte precursor
cells but not in vascular smooth muscle cells (VSMC), endothelial
cells (EC) and any other ecto- or endoderm derived cells. In
agreement with this notion, amplification of the genomic DNA
isolated from double transgenic heart tissue (MC
+p53
F/+ or
MC
+p53
F/F) using 1FA and 10RA primers which span introns
1–10 of p53 gene resulted in a 603 bp product (Fig. 1C). However,
1FA/10RA primer pair failed to amplify any product from cardiac
genomic DNA in the absence of Cre expression (Fig. 1C). As
expected, primers specific for both intron 10 (10FA/10RA) and
intron 1 (1FA/1RA) were also able to amplify appropriate size
PCR fragments from cardiac genomic DNA of the double
transgenic hearts accounting for intact p53 floxed alleles present
in non-cardiomyocyte cell types (Fig. 1C). There was no evidence
of altered cardiac growth either in MC
+p53
F/+ or MC
+p53
F/F
compared to wild type BL6 mice (11–15 week old mice were
examined). Similarly, histological analyses did not reveal any overt
changes such as hypertrophy or fibrosis as a result of genetic
modifications in double transgenic hearts (data not shown).
Furthermore, the cardiac specific p53 CKO mice did not develop
tumors such as those frequently observed in conventional p53
knockouts [28].
Assessment of p53 expression profiles and apoptosis
levels in wild type and p53 CKO hearts treated with or
without Doxorubicin
Consistent with previous studies [23,33], we observed very low
levels of p53 expression in untreated and saline treated wild type
or CKO mouse hearts using immune histology and western blot
analysis methods (Fig. 2A and D). In case of wild type hearts
treated with Dox, p53 expression was readily detectable in both
nuclear and cytoplasmic compartments of cardiomyocytes as well
as vascular cells at 3 and 6 hrs post drug treatment (Fig. 2B and
C). In contrast to wild type hearts, p53 immunostaining was
observed only in vascular cells but not in cardiomyocytes of
MC
+p53
F/F CKO mice (Fig. 3A). Parallel sections processed for
VWF staining confirmed that endothelial cells account in part for
the increased levels of p53 observed in myocardial blood vessels
(Fig. 3B). The VWF staining intensity was much higher in Dox
treated hearts compared to untreated or saline treated hearts.
Further, VWF immunostaining revealed high concentrations of
protein in subendothelial matrix (Fig. 3B). Based upon western
blotting studies, p53 protein levels decreased in both wild type and
CKO mice after 7 days of Dox treatment and were comparable to
those observed in control hearts (Fig. 2D).
The cardiotoxic effects of Dox are partly attributed to induction
of apoptotic pathways involving p53 [13,21,22]. A hallmark of
apoptosis is activation of endonucleases that are responsible
cleavage of chromosomal DNA at internucleosomal linker regions.
To determine the levels of apoptosis in Dox treated hearts, a
TUNEL assay was used. This assay is based on the detection of
single or double stranded DNA breaks by in situ terminal
deoxynucleotidyl transferase labelling with a fluorochrome which
allows apoptotic nuclei to be readily distinguished from healthy
nuclei. While control sections showed very low levels of TUNEL
activity, considerably larger number of TUNEL positive nuclei
were detected in Dox treated wild type hearts from 3 and 7 day
time points (,100–200 per square millimetre). A similar level of
apoptosis was also detected in sections from Dox treated p53 CKO
mice. Interestingly, TUNEL positive nuclei were found in
cardiomyocytes, interstitial and vascular regions after Dox
treatment independent of p53 status in all experimental groups
(Fig. 3D and E).
Figure 2. Expression of p53 in the heart after Dox treatment.
(A) Very low levels of p53 immunostaining were observed in the control
untreated heart. (B and C) Increased expression of p53 was evident in
cytoplasmic and nuclear compartments of cardiomyocytes in hearts
treated with Dox for 3 or 6 hrs. Bar, 20 mm (A–C). (D) Western blot
analysis of p53 protein levels in wild type (WT) and p53 conditional
knockout (MC
+ and p53
F/F or
F/+) hearts treated with saline (S) or Dox (D)
for 3 days (3 d) or 7 days (7 d). A 25 kD band from Naphthol Blue Black
stained blots was used as a loading control (LC) for protein loading.
doi:10.1371/journal.pone.0022801.g002
Figure 3. Expression of p53 and TUNEL staining in vascular
cells after 3 day Dox treatment in MC
+ p53
F/F conditional
knockout hearts. Cardiac sections were processed for p53 (A), VWF
(B) and nuclear (C) staining. Bar, 50 mm (A–C). (D) Examples of TUNEL
positive vascular cells in MC
+ p53
F/+ hearts after 3 day Dox treatment.
(E) Examples of TUNEL positive cardiomyocytes in MC
+ p53
F/F hearts.
Bars, 50 mm, D and E.
doi:10.1371/journal.pone.0022801.g003
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active caspase 3 (Casp3
+) indicated that both cardiomyocytes and
vascular cells can undergo caspase dependent apoptosis in Dox
treated wild type and p53 CKO mice (Fig. 4). Compared to the
control value, number of Casp3
+ cardiomyocytes per mm
2 was
significantly higher in Dox treated wild type or p53 CKO hearts at
3 day time point (,2o r,5 fold respectively, Fig. 4B). Further,
Casp3
+ numbers in Dox treated MC
+p53
F/F hearts were
significantly higher (,2 fold) than those observed in Dox treated
wild type hearts (Fig. 4B).
Assessment of ROS and 3-NT levels in wild type and p53
CKO hearts treated with or without Doxorubicin
Given the increased levels of myocardial apoptosis in p53 CKO
hearts, we subsequently examined the levels of ROS by DHE
staining (Fig. 5). Membrane permeable DHE has been widely used
as a detection probe for superoxide and other ROS, since its
oxidation product ethidium can be readily detected by fluores-
cence microscopy [7,32]. DHE fluorescence signal was observed
mainly in endothelial and smooth muscle cells of wild type saline
treated hearts at 3 day time point (Fig. 5A). In contrast, DHE
staining was observed at a higher frequency in vascular cells as well
as cardiomyocytes in the hearts of Dox treated wild type or p53
CKO mice (Fig. 5B, C). To assess the nitrosactive stress caused by
peroxinitrite pathway, sections were also examined using 3-NT
immunohistochemical staining. Compared to a smaller number of
3-NT positive cells in saline treated hearts, a higher frequency of
3-NT positive cardiomyocytes and vascular cells was observed in
Dox treated wild type and p53 CKO hearts at 3 day time point
(Fig. 5D–F). These findings collectively suggest that Dox treatment
can increase ROS and RNS generation and trigger caspase
dependent apoptosis independent of p53 status in cardiomyocytes.
Assessment of cardiac fibrosis levels in wild type and p53
CKO hearts treated with or without Doxorubicin
Given the higher incidence of apoptosis and free radical
generation in Dox treated p53 CKO hearts, we further examined
whether ablation of p53 in cardiomyocytes is sufficient to prevent
Dox induced cardiac fibrosis. Since adult myocardium lacks
intrinsic regenerative capacity, dead cardiomyocytes are replaced
by scar tissue, a process often referred to as reparative fibrosis
[34,35]. Picro Sirius red (PS) and fast green (FG) stains can be used
to distinguish fibrotic regions from healthy myocardium [29].
Histological sections from wild type and p53 CKO mice were
stained with PSFG stain and examined under a microscope to
identify fibrotic lesions (Fig. 6A–D). Histologically, Dox treatment
induced both reparative and perivascular types of fibrosis in wild
type hearts compared to background level of fibrosis in saline
treated hearts (Fig. 6A,B). In agreement with apoptotic cells found,
both reparative as well as perivascular fibrosis were also observed
in the hearts of Dox treated p53 CKO mice (Fig. 6C, D). In the
presence of sustained catecholamine mediated cardiac injury,
reparative fibrosis was shown to switch into reactive fibrosis, a
process characterized by increased deposition of collagen and
extracellular matrix (ECM) in interstitial areas remote to the site of
injury [29]. Typically, the spread of Dox induced fibrotic lesions
was ,2.5 times smaller than that of Iso induced lesions (Mean
lesion lengths 6 SEM: Dox=303615 mm vs. Iso=815633 mm,
Fig. 6E). Although there was a slight decrease in heart weight to
body weight ratio (HW/BW) of Dox treated wild type mice
compared to saline treated group, Dox treatment did not have any
effect on HW/BW ratios of p53 CKO mice (Fig. 6F).
To quantify the fibrotic areas in tissue sections, CS-CAIA
software was used as previously described [29]. The fibrotic area
from each section was then expressed as percent fibrosis. The
control group for three day time point showed a basal fibrosis of
2% (Fig. 7A). Compared to the control value, the percent fibrosis
was significantly higher in Dox treated wild type or p53 CKO
hearts at 3 day time point (Fig. 7A). Interestingly, fibrosis levels in
Dox treated MC
+p53
F/F hearts were significantly higher (,2 fold)
Figure 4. Caspase dependent apoptosis after 3 day Dox
treatment in MC
+ p53
F/F conditional knockout hearts. (A)
Examples of cardiomyocytes positive for active caspase 3 in myocardial
s e c t i o n s ,B a r ,2 0 mm, (B) Quantification of caspase 3 positive
cardiomyocytes per mm
2 in saline (S) or Dox (D) treated wild type
(WT) or p53 CKO hearts. N=3 mice per group, *P,0.05 compared to
WT(S), #P,0.005 compared to WT(S) or WT(D), ANOVA, Tukey’s
multiple comparisons test.
doi:10.1371/journal.pone.0022801.g004
Figure 5. Dox treatment induces ROS and 3-nitrotyrosine
generation independent of p53 gene status in the heart. (A–C)
Detection of superoxide/ROS after 3 day Dox treatment in frozen
sections of wild type or p53 CKO hearts using dihydroethidium (DHE)
staining. (A, B) DHE positive endothelial or smooth muscle cells in
saline (S) or Dox (D) treated wild type (WT) hearts are indicated by
arrows. (C) Examples of DHE positive cardiomyocytes are indicated by
arrowheads. Bar, 50 mm, A–C. (D–F) Immunostaining of 3-nitrotyrosine
(3-NT) in sections derived from saline (S) or Dox (D) treated WT (D, E)
and p53 CKO (F) hearts at 3 day time point. Note the increase in 3-NT
staining in cardiomyocytes after DOX treatment in both WT and p53
CKO hearts. Bar, 50 mm, D–F.
doi:10.1371/journal.pone.0022801.g005
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point (Fig. 7A). A similar trend in fibrosis levels was also observed
at 7 day time point. Compared to the control fibrosis levels, Dox
treatment led to significantly higher levels of fibrosis in all
experimental groups irrespective of p53 status at 7 day time point
(Fig. 7B). Further, fibrosis levels decreased by 25–50% in Dox
treated hearts at 7 day time point compared to 3 day time point
(Fig. 7A and B). Thus, our results suggest that conditional ablation
of p53 in cardiomyocytes does not offer protection against cardiac
fibrosis induced by Dox.
Assessment of a-tubulin protein levels in wild type and
p53 CKO hearts treated with or without Doxorubicin
Previous studies have shown that administration of a normal
therapeutic dose of Dox can alter the expression profiles of some
cytoskeletal and ECM proteins in the rat heart [36]. Using
cultured chick cardiomyocytes, it was shown that Dox treatment
could lead to damage of microtubule structures and impairment of
microtubule assembly [37]. Given the previous reports on
improved cardiac function after Dox treatment in p53 global
knockout mice, we have examined whether ablation of p53 in
cardiomyocytes is sufficient to prevent microtubule changes
reported earlier. To quantify levels of detergent soluble a-tubulin
protein, cytosolic fractions were prepared from saline or Dox
treated control and p53 CKO mouse hearts at 3 or 7 day time
points, western blotting and densitometry were performed as
described in methods section. We normalized a-tubulin levels to
those of CBF-A as we did not find any significant changes in CBF-
A levels with or without drug treatment in control and p53 CKO
hearts (data not shown). Compared to the control value,
normalized a-tubulin levels were significantly lower (,2–2.5 fold)
in Dox treated wild type or p53 CKO hearts at 3 day time point
(Fig. 8A). However, there was no significant difference in a-tubulin
levels between Dox treated wild type, MC
+p53
F/F or MC
+p53
F/+
hearts (Fig. 8A). Seven days after Dox treatment, a-tubulin levels
in all Dox treated groups returned back to those seen in control
hearts (Fig. 8B). Thus, our results suggest that conditional ablation
of p53 in cardiomyocytes is not adequate to prevent microtubule
changes associated with Dox treatment.
Discussion
Dox undergoes a redox reaction in cardiac mitochondria, where
it is reduced by NADH dehydrogenase to form a semiquinone
compound which is oxidized back to the original structure by
transferring an electron to the molecular oxygen. This process
generates ROS including superoxide, hydrogen peroxide and
hydroxyl radicals (Fig. 9, [3,38]). Excessive superoxide can react
with nitric oxide to generate RNS such as peroxynitrite [3,7,38].
Iron has been shown to promote ROS formation in Dox treated
cells [38]. Further, a variety of factors are known to amplify ROS/
RNS mediated oxidative/nitrosactive stress which leads to strand
breaks in DNA, activation of poly ADP ribose polymerase, DNA
damage, upregulation of redox sensitive transcription factors such
as p53 and NF-kB, changes in mitochondrial permeability,
apoptosis and ultimately cardiotoxicity (Fig. 9, [7,8,39]). Overex-
pression of manganese superoxide dismutase or treatment with
peroxinitrite scavengers have been shown to decrease ROS/RNS
generation and mitochondrial injury [7,40]. While the majority of
Figure 6. Dox treatment induces myocardial fibrosis independent of p53 gene status in the heart. (A–D) Representative
photomicrographs of PSFG stained cardiac sections from wild type or p53 CKO hearts treated with saline (A) or Dox (B–D) at 7 day time point.
Both reparative (C) and perivascular (D) types of fibrosis were evident in Dox treated MC
+ p53
F/F conditional knockout hearts. Bar, 100 mm A–D. (E)
Quantification of the spread of cardiac fibrosis lesions in Dox and Isoporterenol (ISO) treated hearts at 7 day time point. LL: lesion length, LW: lesion
width. ISO induced LL was significantly greater (,2.5 fold) compared to Dox induced LL (n=3–5 mice per group, *P,0.005 compared with other
groups. ANOVA, Tukey’s multiple comparison test). (F) No significant difference is observed between groups in heart weight and body weight ratios
of mice used in these studies at 7 day time point.
doi:10.1371/journal.pone.0022801.g006
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studies have proposed that RNS is the major cause of
cardiotoxicity [7]. Although several experimental strategies have
been suggested for prevention of Dox-induced cardiotoxicity
[3,38], numerous preclinical/clinical studies have led to negative
or mixed outcomes suggesting a role for alternate mechanisms
other than the conventional ROS and iron based hypotheses [38].
Understanding different cytotoxic mechanisms of Dox is critical to
prevent cardiotoxic effects when using this drug for anticancer
therapies. Recent studies have indicated that abating the function
or deleting p53 in myocardium may decrease Dox-induced
cardiotoxicity and improve left ventricular ejection fraction
[21,23]. However, none of these studies directly compared levels
of cardiac fibrosis or incidence of myocardial vascular lesions in
response to drug treatment in animals with intact or deleted p53
gene. This is particularly important since Dox concentrations were
shown to be significantly higher in perivascular areas compared to
hypoxic regions in solid tumors [41]. A similar distribution pattern
of Dox in heart tissue may lead to an increased incidence of
perivascular lesions limiting oxygen supply to adjacent myocytes.
In this study, we found that cardiomyocyte specific disruption of
p53 gene does not reduce levels of free radical generation,
apoptosis and myocardial fibrosis or vascular lesions.
Expression of p53 appears to be tightly regulated in the
myocardium since very low levels of transcripts or protein were
found in normal and hypertrophic murine adult hearts [23,33]. In
contrast, the percentage of immunoreactive p53 nuclei was shown
to significantly increase (,4 fold) in myocardial biopsies obtained
from end-stage heart failure patients compared to those from
normal patients which suggests a role for this cell cycle regulatory
Figure 7. Quantification of cardiac fibrosis in tissue sections after 3 or 7 days of Dox treatment. Percent fibrosis values in PSFG-stained
heart sections were calculated using Image processing Tool Kit software and image analysis was performed on a minimum of ten slides per animal for
each treatment group (n=3–5 mice per group). Dox (D) treatment significantly increased cardiac fibrosis in wild type (WT) and p53 CKO hearts
compared to saline (S) treated hearts after 3 day (A) or 7 day (B) treatment periods. 3 day Dox time point: *P,0.05 compared to WT(S), **P,0.05
compared to WT(D), ANOVA, Tukey’s multiple comparisons test; 7 day Dox time point: #P,0.05 compared to WT(S), ANOVA, Tukey’s multiple
comparison test.
doi:10.1371/journal.pone.0022801.g007
Figure 8. Quantification of a-tubulin levels in the hearts of Dox treated and control mice. Ventricular lysates were analyzed 3 days (A) and
7 days (B) after saline (S) or Dox (D) treatment. The levels of a-tubulin were normalized to those of CBF-A for each sample and ratios were expressed
as fold changes relative to WT(S) (n=3 hearts per group). (A) Following a 3 day treatment period, a-tubulin/CBF-A ratios were significantly lower in
Dox treated hearts (both wild type (WT) and p53 CKO) compared to those ratios in saline treated hearts. *P,0.05 compared to WT(S), ANOVA, Tukey’s
multiple comparison test. (B) Following a 7 day treatment period, a-tubulin/CBF-A ratios were not significantly different between Dox (D) or saline (S)
treated hearts.
doi:10.1371/journal.pone.0022801.g008
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changes in p53 protein levels as well as its phosphorylation status
play a crucial role during Dox induced cardiotoxicity [3,22].
However, there are conflicting reports with regards to timing and
cardiac expression levels of p53 after Dox treatment. For instance,
several studies reported that peak levels of p53 expression ranged
from 3–8 hrs and its expression lasted for 24 hrs to 7 days post
Dox treatment [13,22,23,43]. In this study, we found that p53
expression was readily detectable in both nuclear and cytoplasmic
compartments of cardiomyocytes as early as 3 hrs post Dox
treatment of wild type but not p53 CKO mice (Fig. 2). Compared
to previous reports, we were unable to detect any significant
differences in p53 expression levels between control and Dox
treated hearts during 24 hrs to 7 days after treatment (Fig. 2D).
Such variations in p53 expression can be attributed to differences
in mouse strains and or dosing regimens used in these studies.
Dox treatment also increased p53 levels in vascular endothelial
cells in both wild type and CKO mouse hearts (Fig. 3A).
Consistent with a proapoptosis role for p53, we observed an
increased incidence of Casp3
+ and TUNEL positive vascular cells
with a concomitant increase in perivascular fibrosis in both wild
type and p53 CKO hearts (Figs. 3D and 4). We have also observed
a similar pattern of Dox induced perivascular fibrosis in p53 CKO
generated by an independent cardiomyocyte specific Cre expres-
sion line, Nkx2.5-Cre (data not shown). These observations are
directly in agreement with previous in vitro studies which
documented p53 dependent apoptosis in Dox treated human
umbilical vein endothelial cell cultures [44,45]. Accumulation of
Figure 9. Schematic representation of mechanisms underlying DOX-induced cardiotoxicity. Redox recycling of DOX in mitochondria
results in increased levels of superoxide and subsequent generation of other types of reactive oxygen and nitrogen species (ROS/RNS). Increased
levels of ROS results in activation of NF-kB leading to expression of iNOS and thus increased NO expression. Peroxynitrite formation in both
mitochondria and cytosol leads to activation of stress signaling pathways such as MAPKs. Build-up of ROS results in expression of phosphorylated p53
which in turn activates the BAX gene. BAX is involved in cytochrome c release from the mitochondria which leads to activation of Caspase 3/7
pathway eventually causing apoptosis. In the absence of p53, negative feedback regulation of ROS and iNOS is lost, which leads to upregulation of
reactive oxygen/nitrosactive stress. BAX gene is transcriptionally active in p53 null cells. Excessive ROS/RNS can cause translocation of BAX to
mitochondria eventually leading to apoptosis. Further, p53 plays an essential role in mitochondrial DNA repair, and in the absence of p53 this process
is hindered. Note: * or red arrows denote potential steps effected/involved in Dox induced cell death in p53 CKO cardiomyocytes. O2
.2: superoxide;
ONOO
2: peroxynitrite;
.OH: hydroxyl radical; H2O2: hydrogen peroxide; MnSOD: manganese superoxide dismutase; MAPK: mitogen activated protein
kinase; MAP4: microtubule associated protein 4; iNOS: inducible nitric oxide synthase; Ref1: redox effector factor 1; TF: transcription factor.
doi:10.1371/journal.pone.0022801.g009
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induced vascular damage since elevated levels of VWF were
reported during the course of acute coronary syndrome or
thromboembolyic cardiovascular events [46]. Collectively, our
data shows that myocardial vascular lesions also play a critical role
in Dox induced cardiotoxicity.
In addition to vascular lesions, increased levels of apoptosis were
also observed in cadiomyocytes from Dox treated WT and CKO
hearts. Given the established role of p53 in Dox induced
cardiomyocyte death, it is somewhat unexpected to see an increase
in the number of TUNEL and Casp3 positive cardiomyocytes in
p53 CKO mice. However, this result may be explained in several
ways. First, increased incidence of perivascular lesions may limit
supply of oxygen and nutrients and trigger ischemic cell death in
adjacent cardiomyocytes. Second, recently described but not well
characterized p53 independent cell death pathways [47,48] may
also play a role in Dox induced cardiomyocyte death in p53 CKO
mice. Dox was shown to induce cell death in p53 null Saos-2 cells
via a ROS and Casp3 dependent pathway [49]. Although our data
shows increased activation of Casp3 in p53 CKO cardiomyocytes,
a role for Dox induced calpain dependent and Casp3 independent
cell death pathway cannot be completely ruled out [50]. Third,
contrary to the majority of previous reports, loss of p53 in
cardiomyocytes can compromise cell survival following Dox
treatment. Indeed, a global loss of p53 was shown to increase
cardiomyocyte mitochondrial vulnerability to damage following
Dox treatment [13]. Similarly, loss of p53 was associated with
increased production of ROS and iNOS [51,52] and increased
sensitization to NO induced apoptosis [51] in noncardiac cell types
of p53 knockout mice. Further, loss or downregulation of p53 was
shown to cause excessive oxidative damage of DNA [53]. Taken
together, these studies suggests that p53 regulates a negative
feedback loop which controls the production of cellular ROS and
RNS [51–53]. Based on these earlier studies, absence of p53 in
CKO cardiomyocytes is expected to increase ROS, RNS, DNA
damage and cell death when subjected to Dox treatment.
Consistent with this notion, our data shows significant increases
in ROS/RNS, TUNEL and active Casp3 levels in p53 CKO
cardiomyocytes after Dox treatment. Fourth, ROS and RNS may
directly release cytochrome c from mitochondria [11–13] or
increase the translocation of Bax to mitochondria [54] thus
inducing apoptosis independent of p53. Significant differences in
the levels of ROS/RNS, active Casp3 and fibrosis in Dox treated
p53 CKO hearts compared to Dox treated wild type hearts at 3
day time point clearly supports a protective role for p53 in
cardiomyocytes during Dox induced cardiotoxicity as described in
an earlier report [13].
Loss of collagen matrix and cardiac remodelling have been
shown to occur for several weeks after a single Dox injection
[55,56]. Even after the drug is removed from the circulation and
cardiac tissue, mitochondrial dysfunction, cell death and remod-
elling changes continue to occur due to an amplification of
oxidative and nitrosactive stress pathways [7]. While there is scant
information on the development of myocardial fibrosis in an acute
setting similar to that described in this study, Dox induced cardiac
fibrosis has been reported in several long term studies [57,58].
One of these long term studies showed absence of cardiac fibrosis
in wild type mice 5 days after Dox administration [58]. Such
differences in cardiac fibrosis can be attributed to differences in
mouse strains, starting age for Dox treatment, time points, staining
techniques and dosing regimens used in these studies. Further,
upregulation of different matrix metalloproteases (MMPs 1, 2 and
9) has been reported in both short and long term settings of Dox
treatment in animal and cell culture models [7,59–61]. In the
absence of sufficient quantities of tissue inhibitors of metallopro-
teases (TIMPs), activated MMPs can digest collagen matrix and
ECM and trigger reparative fibrosis in Dox induced or dilated
cardiomyopathy [59,61,62]. Although we have not measured
MMP levels in our study, differences in the time course of MMP
activation may also account for the early onset of fibrosis observed
in our study compared to the absence of fibrosis in the acute
setting of an earlier study [58]. Interestingly, our results showed
that fibrosis levels decreased at 7 days compared to 3 day time
point (Fig. 7A and B). These changes are also likely due to
proteolytic actions of MMPs on provisional reparative fibrosis in
the acute phase of Dox treatment, which may subsequently switch
to a reactive phase of fibrosis in the long run under the influence of
sustained ROS/RNS actions and associated secondary pathways
such as inflammation and neurohumoral signalling events. Indeed,
significance of such secondary events in reactive fibrosis is
underscored by a relatively larger spread of Iso induced fibrotic
lesions compared to that of Dox induced lesions at 7 day time
points (Fig. 6E).
In this study we showed that levels of detergent soluble a-
tubulin monomeric protein were significantly lower in Dox treated
wild type heart lysates compared to those in control group at 3 day
time point and these levels were restored back to control values at
7 day time point. These findings are consistent with a previous
report which documented a similar decrease and restoration of a-
tubulin levels in a rat model of Dox induced cardiotoxicity [36].
Although it was initially proposed that oxidative stress caused by
Dox may be responsible for degradation of a-tubulin [36] or
damage to microtubule system [37], more recent studies using
various cancer cell lines have uncovered a direct link between p53
and microtubular network. Functional microtubules (polymers of
a- and b- tubulins) and dynein were shown to participate in the
nuclear transport of p53 after Dox treatment [63]. Upon entering
the nucleus, p53 was shown to repress transcription of a
microtubule associated protein 4 (MAP4) which is essential for
stabilization of microtubule structures in the cytosol [64].
Consequently, downregulation of MAP4 protein was shown to
increase monomeric pool of tubulins with a shorter half-life [65],
which were long known to exert a negative feedback control on
transcriptional rate of tubulin genes leading to decreased protein
synthesis [66]. While our study has not examined ratios of
polymerized vs. monomeric microtubule proteins, it is possible
that Dox induced decrease in a-tubulin monomers may result
from similar interactions between p53 and microtubule network in
cardiomyocytes and vascular cells. Certainly MAP4 plays a critical
role in stabilization of microtubules during pressure overload
cardiac hypertrophy and associated contractile dysfunction [67].
Overexpression of MAP4 in adult feline cardiomyocytes was
shown to increase the density of microtubule network [68]. In this
context, it is of interest to note that a-tubulin levels also decreased
in Dox treated p53 CKO hearts at 3 day time point and restored
back to control values at 7 day time point. While this result may
suggest a role for p53 independent pathways in regulation of
microtubule stability, it does not rule out similar interactions
between p53 and microtubule network in vascular cells. Given the
well established role of cytoskeletal networks in regulation of
cardiac contractility [69], changes in a-tubulin levels following
Dox treatment may explain in part cardiac functional improve-
ments observed in earlier studies [21,23]. Further studies are
required to understand mechanisms involved in Dox induced
regulation of microtubule network and its role in cardiotoxicity.
Collectively, our results suggest that selective loss of p53 in
cardiomyocyte compartment is not adequate to prevent excessive
free radical generation, myocardial apoptosis, interstitial and
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22801perivascular fibrosis as well as microtubule changes following Dox
treatment. Due to sustained myocardial fibrosis in p53 CKO
hearts, we conclude that there are other p53 independent
apoptotic pathways leading to cardiomyocyte apoptosis. Our data
from p53 CKO cardiomyocytes suggests that excessive reactive
oxygen/nitrosactive stress may directly trigger p53 independent
cell death pathways in Dox induced cardiotoxicity. Further studies
are required to identify the key components of p53-independent
cell death pathways responsible for Dox induced cardiac fibrosis.
Our findings also underscore the importance of vascular lesions in
Dox induced cardiotoxicity and raise a cautionary note for future
strategies involving p53 inhibitors for prevention of cardiac events
in patients undergoing Dox therapy.
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